Clinical Trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer
Protocol Amendment History 5 changes
notable Trial sites reduced: 287 -> 281 locations 2026-07-23
notable Trial sites expanded: 279 -> 286 locations 2026-05-29
critical Primary endpoint(s) modified 2026-05-07
notable Trial sites expanded: 263 -> 279 locations 2026-05-07
notable Trial sites expanded: 254 -> 263 locations 2026-04-01
Trial Details
NCT Number NCT07221357
Lead Sponsor Bristol-Myers Squibb
Collaborators: BioNTech SE
Conditions Untreated, Unresectable, or Metastatic Colorectal Cancer
Enrollment 990 participants
Start Date 2025-12-31
Primary Completion 2030-02-02 (estimated)
Study Completion 2034-03-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-22